Turnstone Biologics
TSBX
TSBX was delisted on the 8th of August, 2025.
23 hedge funds and large institutions have $3.03M invested in Turnstone Biologics in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 23 → 23 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
8.48% less ownership
Funds ownership: 44.93% → 36.45% (-8.5%)
29% less capital invested
Capital invested by funds: $4.26M → $3.03M (-$1.23M)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$73.2K |
| 2 |
DAM
Deltec Asset Management
New York
|
+$37.2K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$18.9K |
| 4 |
GS
GTS Securities
New York
|
+$15.8K |
| 5 |
HF
HRT Financial
New York
|
+$15.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$382K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$312K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$151K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$21.7K |
| 5 |
Millennium Management
New York
|
-$15.9K |
TSBX Hedge Fund Activity: Q2 2025 in Review
23 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Turnstone Biologics (TSBX) for Q2 2025, worth a combined $3.03M — down 29% from $4.26M a quarter earlier.
Fund positioning in TSBX was balanced in Q2 2025: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 8 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $73.2K. The largest seller was PFM Health Sciences, exiting entirely with an estimated $382K sold.
- 23 institutional investors held Turnstone Biologics (TSBX) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $3.03M of Turnstone Biologics stock for Q2 2025, down 29% quarter-over-quarter.
- 3 funds opened new Turnstone Biologics positions in Q2 2025 and 3 closed out, a net change of 0 holders.
- The largest Turnstone Biologics buyer in Q2 2025 was Citadel Advisors, an estimated $73.2K added.
- The largest Turnstone Biologics seller in Q2 2025 was PFM Health Sciences, an estimated $382K sold.
Based on aggregated 13F filings for Q2 2025.